Skip to main content
Thursday, 29 October 2026AboutBecome a reporterContact
GARUD Times
Live

Choose your state

See stories from where you live.

EN
Unconfirmed

Why India rejected a patent application for shorter drug-resistant TB treatment | Explained

The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care

The Hindu · · 1 min read ·

Why India rejected a patent application for shorter drug-resistant TB treatment | Explained
Why India rejected a patent application for shorter drug-resistant TB treatment | Explained (Image: The Hindu)

The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care

More in India